

## Global TB Caucus Position on the G20

The Global TB Caucus is an international network of more than 2,300 parliamentarians from over 130 countries. Its members work collectively and individually to accelerate progress against the tuberculosis (TB) epidemic. The G20 nations, as the world's largest economies and home to more than fifty per cent of the world's cases of TB, must show greater leadership if we are to achieve success in the fight against TB. We, therefore, call on the G20 nations, under the leadership of the government of Argentina, to include the following statements in their 2018 Leaders' Communique:

### On Universal Health Coverage (UHC)

We recognise that strong public health systems to tackle infectious diseases, and particularly HIV/AIDS, TB and malaria, are pre-requisites for the delivery of universal health coverage. We acknowledge that a country's rate of TB is a key indicator of the strength of its health system and that investments in TB care and prevention can leave a legacy of stronger health systems and represent an important stepping stone towards the achievement of universal health coverage. We recognise the Global Fund to Fight HIV/AIDS, TB and Malaria as having a key role in efforts to tackle these diseases and strengthen health systems and commit to supporting a successful replenishment of the Global Fund in 2019.

### On Antimicrobial Resistance (AMR)

We recognise drug-resistant tuberculosis as a key component of the global threat of AMR and that the prevention, diagnosis and treatment of all forms of tuberculosis is central to preventing the further development and spread of drug-resistance and ensuring global health security. We commit to scaling up diagnosis and treatment of all forms of TB to achieve the targets agreed in the United Nations High-Level Meeting on Tuberculosis in 2018 and to ensure that the Sustainable Development Goal target to end TB by 2030 is realised. We recognise the need to urgently develop and promote access to new drugs, diagnostics and vaccines to tackle drug-resistant TB, and affirm that to further these efforts, addressing drug-resistant TB will be a central component of the focus of the AMR R&D collaboration hub established during the 2017 German Presidency.